In addition to SGLT2 inhibitors and GLP-1 receptor agonists, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, has demonstrated significant cardiovascular and kidney-protective effects in people with type 2 diabetes mellitus and CKD or HF [129-132]
We take the time to understand your health, habits, and goals, crafting a plan that makes sense for you
once-daily dosing for basal coverage Bolus/prandial insulins: Insulin lispro, aspart, glulisine
Real-World Patient Experiences and Choosing the Right Medication What Clinical Guidelines Recommend Professional societies now position GLP-1 medications prominently in treatment algorithms
Clinical studies indicate that alterations in the microbiome precede and forecast treatment responses, implying the possibility for individualized therapeutic strategies based on initial microbiotic profiles (Perraudeau et al
Ro has collaborations with both Eli Lilly and Novo Nordisk , which allow for streamlined access to FDA-approved options, such as the Zepbound KwikPen, Foundayo, and Wegovy (pen and pill)